

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

Brilliant Violet 605(TM) anti-mouse CD45

RRID:AB_2562342

Type: Antibody

Proper Citation

BioLegend Cat# 103140, RRID:AB_2562342

Antibody Information

URL: http://antibodyregistry.org/AB_2562342

Proper Citation: BioLegend Cat# 103140, RRID:AB_2562342

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-mouse CD45

Description: This monoclonal targets CD45

Target Organism: mouse

Clone ID: Clone 30-F11

Antibody ID: AB_2562342

Vendor: BioLegend

Catalog Number: 103140

Alternative Catalog Numbers: 103155, 103139

Record Creation Time: 20250820T031611+0000

Record Last Update: 20250820T154802+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-mouse CD45.

No alerts have been found for Brilliant Violet 605(TM) anti-mouse CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Scott-Solomon E, et al. (2026) Stress-induced sympathetic hyperactivation drives hair follicle necrosis to trigger autoimmunity. *Cell*, 189(1), 252.

Heaton AR, et al. (2026) Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors. *bioRxiv : the preprint server for biology*.

Silva Angulo F, et al. (2025) Rev-erb- α antagonism in alveolar macrophages protects against pneumococcal infection in elderly mice. *Cell reports*, 44(2), 115273.

Xie M, et al. (2025) Tumor-resident probiotic *Clostridium butyricum* improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. *Cancer cell*.

Song B, et al. (2025) Histotripsy-Focused Ultrasound Treatment Abrogates Tumor Hypoxia Responses and Stimulates Antitumor Immune Responses in Melanoma. *Molecular cancer therapeutics*, 24(7), 1088.

Yamane K, et al. (2025) ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity. *International journal of molecular sciences*, 26(7).

Song Q, et al. (2025) *Bifidobacterium animalis* suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid. *Cell reports*, 44(8), 116132.

Osaki M, et al. (2025) Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity. *Immunity*, 58(4), 889.

Morikis VA, et al. (2025) Cadherin-1-mediated communication at the leader-follower boundary controls mouse breast tumor organoid collective migration. *Cell reports*, 44(12), 116631.

Lai P, et al. (2025) Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven immunosuppression through the cGAS-STING pathway. *Immunity*, 58(4),

Pozniak J, et al. (2025) Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype. *Cancer discovery*, 15(9), 1819.

Benamar M, et al. (2025) Notch3 destabilizes regulatory T cells to drive autoimmune neuroinflammation in multiple sclerosis. *Immunity*, 58(11), 2753.

Matsushita M, et al. (2025) Peroxisomes are critical for a unique metabolic demand and survival of alveolar macrophages. *Cell reports*, 44(5), 115623.

Pan S, et al. (2025) Decoding the ontogeny of myeloid lineage diversity by cross-species and developmental analyses of hematopoietic progenitor atlases. *Cell reports*, 44(3), 115406.

Lin Y, et al. (2024) Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response. *Med (New York, N.Y.)*, 100530.

Rebeck ON, et al. (2024) A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden. *Cell chemical biology*.

Morita S, et al. (2024) Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma. *Cancer immunology research*.

Kim TS, et al. (2024) Epithelial-derived interleukin-23 promotes oral mucosal immunopathology. *Immunity*.

Calì B, et al. (2024) Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. *Cancer cell*, 42(10), 1676.

Case JB, et al. (2024) A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice. *Cell host & microbe*, 32(12), 2131.